We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
Read MoreHide Full Article
Key Takeaways
PFE expects revenue headwinds in 2026-2030 as major drugs like Eliquis and Ibrance lose patent protection.
PFE's oncology pipeline has several late-stage candidates.
PFE is expanding its obesity portfolio through the Metsera acquisition and a GLP-1 deal with YaoPharma.
Pfizer (PFE - Free Report) expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) of several of its key products in the 2026-2030 period. These include Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, all of which face patent expirations.
However, the company has strengthened its R&D pipeline through M&A deals, successful data readouts and pivotal program starts in 2025, which, it believes, will position it for sustainable growth in the post-LOE period.
PFE’s Strong Oncology Pipeline
Pfizer has particularly advanced its oncology pipeline with several candidates entering late-stage development. Key oncology candidates in late-stage development include vepdegestrant (a small-molecule PROTAC for ER+/HER2- metastatic breast cancer), atirmociclib (a CDK4 inhibitor for 1st line HR+/HER2- metastatic breast cancer) and sigvotatug vedotin (an antibody-drug-conjugate or ADC for metastatic non-small cell lung cancer).
Sasanlimab for the treatment of BCG-naive high-risk non-muscle invasive bladder cancer is under review in the United States and the EU. This year, it in-licensed exclusive global ex-China rights to develop, manufacture and commercialize PF-08634404, a dual PD-1 and VEGF inhibitor, from China’s 3SBio. Dual PD-1/VEGF inhibitors have been designed to overcome the limitations of single-target cancer therapies like Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda and have the potential to become the new standard of care oncology treatments.
By 2030, Pfizer expects to have eight or more blockbuster oncology medicines in its portfolio.
In non-oncology areas, an mRNA flu/COVID combination vaccine and osivelotor for sickle cell disease are in late-stage development.
Pfizer is also working on expanding the labels of approved products like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others. Last month, Pfizer's key drug, Padcev, was approved by the FDA in combination with MRK’s Keytruda for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.
PFE Strengthens Obesity Pipeline in 2025
Importantly, Pfizer is strengthening its presence in the obesity market, currently dominated by Eli Lilly and Novo Nordisk. The $10 billion Metsera acquisition in November added four novel clinical-stage incretin and amylin programs for obesity, which are expected to generate billions of dollars in peak sales. Earlier this month, Pfizer in-licensed exclusive global rights to develop YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) for treating obesity from Chinese biotech YaoPharma. With the Metsera acquisition, the YaoPharma deal and other Pfizer programs that include a GIPR antagonist candidate, Pfizer believes it has a robust and diverse obesity portfolio.
Despite near-term revenue pressure from upcoming patent expirations, Pfizer’s expanding late-stage pipeline, led by oncology and supported by growing investments in obesity, vaccines, and rare diseases, positions it for sustainable long-term growth.
Competition in the Oncology Space
Pfizer is one of the largest drugmakers of cancer medicines. Other large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck, J&J (JNJ - Free Report) and Bristol-Myers.
For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first nine months of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for more than 50% of Merck’s pharmaceutical sales. Keytruda recorded sales of $23.3 billion in the first nine months of 2025, up 8% year over year.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo’s sales rose 8% to $7.54 billion in the nine months of 2025.
J&J’s oncology sales now comprise around 27% of its total revenues. Its oncology sales rose 20.6% on an operational basis in the first nine months to $18.52 billion. While J&J’s older cancer drugs, multiple myeloma treatment Darzalex and prostate cancer drug, Erleada, are key contributors to its top-line growth, new drugs such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, hold the key for long-term growth.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has declined 7% in the past year against an increase of 16.0% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.18 forward earnings, lower than 17.40 for the industry and the stock’s 5-year mean of 10.39.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $3.07 per share to $3.10 per share, while that for 2026 has declined from $3.15 per share to $3.04 per share over the past 60 days.
Image: Bigstock
PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
Key Takeaways
Pfizer (PFE - Free Report) expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) of several of its key products in the 2026-2030 period. These include Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, all of which face patent expirations.
However, the company has strengthened its R&D pipeline through M&A deals, successful data readouts and pivotal program starts in 2025, which, it believes, will position it for sustainable growth in the post-LOE period.
PFE’s Strong Oncology Pipeline
Pfizer has particularly advanced its oncology pipeline with several candidates entering late-stage development. Key oncology candidates in late-stage development include vepdegestrant (a small-molecule PROTAC for ER+/HER2- metastatic breast cancer), atirmociclib (a CDK4 inhibitor for 1st line HR+/HER2- metastatic breast cancer) and sigvotatug vedotin (an antibody-drug-conjugate or ADC for metastatic non-small cell lung cancer).
Sasanlimab for the treatment of BCG-naive high-risk non-muscle invasive bladder cancer is under review in the United States and the EU. This year, it in-licensed exclusive global ex-China rights to develop, manufacture and commercialize PF-08634404, a dual PD-1 and VEGF inhibitor, from China’s 3SBio. Dual PD-1/VEGF inhibitors have been designed to overcome the limitations of single-target cancer therapies like Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda and have the potential to become the new standard of care oncology treatments.
By 2030, Pfizer expects to have eight or more blockbuster oncology medicines in its portfolio.
In non-oncology areas, an mRNA flu/COVID combination vaccine and osivelotor for sickle cell disease are in late-stage development.
Pfizer is also working on expanding the labels of approved products like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others. Last month, Pfizer's key drug, Padcev, was approved by the FDA in combination with MRK’s Keytruda for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.
PFE Strengthens Obesity Pipeline in 2025
Importantly, Pfizer is strengthening its presence in the obesity market, currently dominated by Eli Lilly and Novo Nordisk. The $10 billion Metsera acquisition in November added four novel clinical-stage incretin and amylin programs for obesity, which are expected to generate billions of dollars in peak sales. Earlier this month, Pfizer in-licensed exclusive global rights to develop YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) for treating obesity from Chinese biotech YaoPharma. With the Metsera acquisition, the YaoPharma deal and other Pfizer programs that include a GIPR antagonist candidate, Pfizer believes it has a robust and diverse obesity portfolio.
Despite near-term revenue pressure from upcoming patent expirations, Pfizer’s expanding late-stage pipeline, led by oncology and supported by growing investments in obesity, vaccines, and rare diseases, positions it for sustainable long-term growth.
Competition in the Oncology Space
Pfizer is one of the largest drugmakers of cancer medicines. Other large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck, J&J (JNJ - Free Report) and Bristol-Myers.
For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first nine months of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for more than 50% of Merck’s pharmaceutical sales. Keytruda recorded sales of $23.3 billion in the first nine months of 2025, up 8% year over year.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo’s sales rose 8% to $7.54 billion in the nine months of 2025.
J&J’s oncology sales now comprise around 27% of its total revenues. Its oncology sales rose 20.6% on an operational basis in the first nine months to $18.52 billion. While J&J’s older cancer drugs, multiple myeloma treatment Darzalex and prostate cancer drug, Erleada, are key contributors to its top-line growth, new drugs such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, hold the key for long-term growth.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has declined 7% in the past year against an increase of 16.0% for the industry.
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.18 forward earnings, lower than 17.40 for the industry and the stock’s 5-year mean of 10.39.
The Zacks Consensus Estimate for 2025 earnings has risen from $3.07 per share to $3.10 per share, while that for 2026 has declined from $3.15 per share to $3.04 per share over the past 60 days.
Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.